Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:04 2024-04-19 am EDT			5-day change	1st Jan Change
3 ^EUR	+1.35%		-1.64%	-19.79%

Mar. 27	Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment	MT
Mar. 25	Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024

Heidelberg Pharma AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

November 23, 2017 at 04:30 am EST

DGAP Total Voting Rights Announcement: Heidelberg Pharma AG / Total Voting Rights Announcement
Heidelberg Pharma AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

23.11.2017 / 10:27
Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of total number of voting rights

1. Details of issuer

Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany

2. Type of capital measure

	Type of capital measure	Date of status / date of effect
	Conditional capital increase (Sec. 26a para. 2 WpHG)
X	Other capital measure (Sec. 26a para. 1 WpHG)	22 Nov 2017

3. New total number of voting rights:

22.452.570

23.11.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Heidelberg Pharma AG
	Schriesheimer Str. 101
	68526 Ladenburg
	Germany
Internet:	www.heidelberg-pharma.com


End of News	DGAP News Service

632067 23.11.2017

Latest news about Heidelberg Pharma AG

Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment	Mar. 27	MT
Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024	Mar. 25
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 24	CI
Heidelberg Pharma Concludes Royalty Purchase Deal with HealthCare Royalty	Mar. 19	MT
Heidelberg Pharma CEO to Retire; Chief Scientific Officer Named Successor	Nov. 29	MT
Heidelberg Pharma Unit Secures European Patent for Amanitin Toxin-Based Antibody-Drug Conjugates	Nov. 15	MT
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2023	23-10-12	CI
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101	23-09-19	CI
Heidelberg Pharma Gets Milestone Payment for Antibody Technology	23-08-08	MT
Transcript : Heidelberg Pharma AG, H1 2023 Earnings Call, Jul 13, 2023	23-07-13
Heidelberg Pharma AG Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-13	CI
Heidelberg Pharma Ag Announces Executive Changes	23-05-08	CI
Germany's Heidelberg Pharma Appoints CFO	23-05-05	MT
Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-12	CI
Heidelberg Pharma AG Provides Earnings Guidance for the Year 2023	23-03-27	CI
Transcript : Heidelberg Pharma AG, 2022 Earnings Call, Mar 27, 2023	23-03-27
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-23	CI
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-23	CI
Heidelberg Pharma AG Auditor Raises 'Going Concern' Doubt	23-03-23	CI
Transcript : Heidelberg Pharma AG - Special Call	23-02-15
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform	22-12-16	CI
Heidelberg Pharma Ag Announces Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology	22-12-13	CI
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2022	22-10-13	CI
Heidelberg Pharma Unit Signs License Deal With Japan's Takeda For Antibody Targeted Amanitin Conjugate	22-09-12	MT
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma	22-07-14	MT

Chart Heidelberg Pharma AG

Duration

Period

More charts

Company Profile

Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Sector

Biotechnology & Medical Research

Calendar

2024-04-23 - R&D Day

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3 EUR

Average target price

11.3 EUR

Spread / Average Target

+276.67%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEIDELBERG PHARMA AG	-19.79%	147M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs